真实世界房颤消融的CABANA试验普适性评估
P<0.001),在符合试验条件的患者中风险降低更明显。
要点
- 真实世界中消融与复合终点风险降低相关(HR 0.75)。
- 73.8%患者可能符合试验条件,其消融风险降低更明显(HR 0.70)。
- 不符合纳入标准者事件率低且消融无显著关联(HR 0.67,P=0.35)。
核心结论
- 常规临床中消融与CABANA主要复合终点风险降低相关,尤其在符合试验条件的患者中。
主要发现
- 消融与全因死亡、卒中、大出血和心脏骤停复合终点风险降低相关(HR 0.75,95%CI 0.70-0.81;P<0.001)。
- 73.8%患者可能符合试验条件,其中消融相关风险降低最明显(HR 0.70,95%CI 0.63-0.77;P<0.001)。
- 3.8%不符合纳入标准者(65岁以下无卒中危险因素)事件率低且消融无显著关联(HR 0.67,95%CI 0.29-1.56;P=0.35)。
- 22.4%符合至少一项排除标准者消融相关风险降低较小但仍显著(HR 0.85,95%CI 0.75-0.95;P=0.01)。
临床怎么用
- 真实世界数据支持对符合CABANA条件的房颤患者考虑消融以降低复合终点风险。
- 对不符合纳入标准的低危年轻患者,消融获益不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial aimed to assess the impact of ablation on morbidity and mortality. This observational study was conducted in parallel to CABANA to assess trial generalizability. METHODS AND RESULTS: Using a large US administrative database, we identified 183 760 patients with atrial fibrillation (AF) treated with ablation or medical therapy (antiarrhythmic or rate control drugs) between 1 August 2009 and 30 April 2016 (CABANA enrolment period). Propensity score weighting was used to balance patients treated with ablation (N = 12 032) or medical therapy alone (N = 171 728) on 90 dimensions. Ablation was associated with a reduction in the composite endpoint of all-cause mortality, stroke, major bleeding, and cardiac arrest [hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.70-0.81; P < 0.001]. The majority of patients (73.8%) were potentially trial eligible; among whom the risk reduction associated with ablation was greatest (HR 0.70, 95% CI 0.63-0.77; P < 0.001). Among the 3.8% of patients who failed to meet the inclusion criterion, i.e. patients under 65 years without stroke risk factors, the event rates were low and there was no significant relationship with ablation (HR 0.67, 95% CI 0.29-1.56; P = 0.35). Among the 22.4% patients who met at least one of the trial exclusion criteria, there was a lesser but statistically significant reduction associated with ablation (HR 0.85, 95% CI 0.75-0.95; P = 0.01). CONCLUSION: In routine clinical care, ablation was associated with a reduction in the primary CABANA composite endpoint of all-cause mortality, stroke, major bleeding, and cardiac arrest, particularly in patients who were eligible for the trial.
引用
- Noseworthy PA, Gersh BJ, Kent DM, et al. Atrial fibrillation ablation in practice: assessing CABANA generalizability. Eur Heart J. 2019. PMID: 30875424. doi:10.1093/eurheartj/ehz085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。